|Videos|January 5, 2018

Results for Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.


Latest CME